Alpha Teknova Reports 13% Q1 Revenue Growth, Improved Profitability, and Reaffirms 2026 Guidance
summarizeSummary
Alpha Teknova, Inc. announced strong first quarter 2026 financial results, including a 13% increase in revenue and significant improvements in gross margin, Adjusted EBITDA, and Free Cash Outflow, while reaffirming its full-year guidance.
check_boxKey Events
-
Strong Q1 2026 Revenue Growth
Total revenue for the first quarter 2026 increased by 13% to $11.1 million, compared to $9.8 million in the prior year period.
-
Improved Profitability Metrics
Gross profit rose to $3.8 million (34.2% margin) from $3.0 million (30.7% margin) in Q1 2025. Adjusted EBITDA improved to negative $2.0 million from negative $2.5 million year-over-year.
-
Reduced Cash Outflow
Free Cash Outflow decreased to $3.6 million for the quarter, an improvement from $4.3 million in Q1 2025.
-
2026 Guidance Reaffirmed
The company reiterated its fiscal year 2026 revenue guidance of $42 million to $44 million and anticipates Free Cash Outflow of less than $10 million.
auto_awesomeAnalysis
Alpha Teknova's first quarter 2026 financial results show continued operational improvements, building on the positive trends from fiscal year 2025. The 13% revenue growth, coupled with better gross margins and reduced cash burn, indicates progress towards sustainable financial health. Reaffirming the full-year revenue and Free Cash Outflow guidance provides investors with confidence in management's outlook despite ongoing net losses. The routine update to the Code of Ethics is administrative and does not impact the company's financial or operational standing. Investors should monitor the company's ability to maintain this growth trajectory and further reduce its net loss and cash outflow in subsequent quarters.
At the time of this filing, TKNO was trading at $3.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $195.1M. The 52-week trading range was $1.91 to $7.48. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.